Similar Search Results

Price dynamics of Swedish pharmaceuticals

Janssen, Aljoscha - 2020

This paper investigates price patterns of off-patent pharmaceuticals in Sweden. I show that price dynamics are … competition in which the demand for pharmaceuticals incorporates the known biases of consumers: habit persistence and brand … preferences. Using the regulated market of Swedish pharmaceuticals, I show that price may help in identifying possible tacit …

Persistent link: https://www.econbiz.de/10012181078

Switching costs, brand premia and behavioral pricing in the pharmaceutical market

Janssen, Aljoscha - 2020

mimics a reduction of switching costs and increases prices. While the effect of switching costs on prices in theory is …

Persistent link: https://www.econbiz.de/10012161505

The effect of higher out-of-pocket payments on drug prices and demand

Loetscher, Fabienne; Schmid, Christian; Gerfin, Michael - 2024

, Switzerland introduced out-of-pocket price differentiation. As of July 1st 2011, substitutable pharmaceuticals with prices above a …

Persistent link: https://www.econbiz.de/10014551351

Switching Costs, Brand Premia and Behavioral Pricing in the Pharmaceutical Market

Janssen, Aljoscha - 2020

mimics a reduction of switching costs and increases prices. While the effect of switching costs on prices in theory is …

Persistent link: https://www.econbiz.de/10014095430

Excessive Pricing of Pharmaceuticals in EU Law : Balancing Competition, Innovation and Regulation

Akker, Ilan; Sauter, Wolf - 2022

Abstract: This article discusses the prosecution of excessive pricing cases regarding pharmaceutical products under EU law in its regulatory context. In recent years the legal framework for the pursuit of such cases, based on the United Brands precedent, has been established more firmly. The...

Persistent link: https://www.econbiz.de/10013299479

The effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-Day exclusivity period

Olson, Luke M.; Wendling, Brett W. - 2013

Persistent link: https://www.econbiz.de/10010473653

The Information Prescription for Drug Regulation

Bernstein, Anita; Bernstein, Joseph - 2013

Before it can sell a prescription drug lawfully in interstate commerce, a manufacturer must prove to the satisfaction of the Food and Drug Administration that the drug is both safe and effective. Congress approved this requirement in 1962 unanimously. Four decades of changes in the drug market...

Persistent link: https://www.econbiz.de/10014058315

Does reference pricing drive out generic competition in pharmaceutical markets? : evidence from a policy reform

Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune - 2022

Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...

Persistent link: https://www.econbiz.de/10013285854

Estimating the causal effect of entry on generic drug prices using Hatch-Waxman exclusivity

Olson, Luke M.; Wendling, Brett W. - In: Review of industrial organization : RIO 53 (2018) 1, pp. 139-172

Persistent link: https://www.econbiz.de/10012009099

The unexpected consequences of generic entry

Castanheira, Micael; Ornaghi, Carmine; Siotis, Georges - 2019

Persistent link: https://www.econbiz.de/10012179614